| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Nov'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue from product sales | |||||||||||
- | - | - | - | - | - | - | - | - | 662 | 499 | 384 |
Revenue from licensing agreements | |||||||||||
- | - | - | - | - | - | 1,012 | 172 | - | 1,220 | 1,426 | 992 |
Revenue from licensing agreements, grants and other | |||||||||||
- | - | - | - | - | - | - | - | 489 | 557 | 927 | 608 |
Cost of product sales | |||||||||||
- | - | - | - | - | - | - | - | - | 214 | 168 | 261 |
Gross profit | |||||||||||
- | - | - | - | - | - | - | - | - | 1,005 | 1,258 | 731 |
Research and development | |||||||||||
3,048 | 2,515 | 1,100 | 901 | -823 | 836 | 21,503 | 19,368 | 14,682 | 19,937 | 21,019 | 19,929 |
General and administrative | |||||||||||
4,192 | 4,729 | 4,167 | 8,734 | -92 | 251 | 10,419 | 8,834 | - | - | - | - |
Selling, general and administrative | |||||||||||
- | - | - | - | - | - | - | - | 7,359 | 8,202 | 9,376 | 9,530 |
Wind-down expense | |||||||||||
- | - | - | - | - | - | - | 61 | 356 | 287 | 221 | 649 |
Impairment of intangible asset | |||||||||||
- | - | - | - | - | - | - | - | - | 654 | - | - |
Total operating expenses | |||||||||||
- | - | - | - | - | - | 31,922 | 28,264 | 22,398 | 29,082 | 30,618 | 30,109 |
Operating loss | |||||||||||
-7,240 | -7,244 | 5,267 | -9,635 | 915 | -1,087 | -30,910 | -28,092 | -21,908 | -28,076 | -29,359 | -29,378 |
Financing expenses, net | |||||||||||
-103 | -16 | 2,322 | - | - | - | - | - | - | - | - | - |
Capital Gain | |||||||||||
96 | - | - | - | - | - | - | - | - | - | - | - |
Net loss and comprehensive loss | |||||||||||
- | - | 7,589 | - | - | - | - | - | - | - | - | - |
Financing income (expenses), net | |||||||||||
- | - | - | 28 | 6 | 119 | - | - | - | - | - | - |
Realized gain on sale of marketable securities | |||||||||||
- | - | - | - | - | - | - | - | - | 83 | - | 406 |
Change in fair value of warrant liability | |||||||||||
- | - | - | - | - | - | -2,422 | -3,253 | 5,944 | -6,612 | - | - |
Impairment of goodwill | |||||||||||
- | - | - | - | - | - | 1,910 | - | - | - | - | - |
Impairment of other intangible assets | |||||||||||
- | - | - | - | - | - | 530 | - | - | - | - | - |
Change in fair value of warrant liability | |||||||||||
- | - | - | - | - | - | - | - | - | - | 3,005 | 1,898 |
Interest income | |||||||||||
- | - | - | - | - | - | 8 | 11 | 15 | 13 | 26 | 67 |
Interest expense | |||||||||||
- | - | - | - | - | - | 1,295 | 1,166 | 50 | 71 | 93 | 110 |
Qualifying therapeutic discovery project grant | |||||||||||
- | - | - | - | - | - | - | - | - | - | 977 | - |
Other income (expense), net | |||||||||||
- | - | - | - | - | - | -45 | 8 | -83 | 109 | 199 | 89 |
Total other income (expense), net | |||||||||||
- | - | - | - | - | - | -1,350 | 2,106 | -6,062 | 6,747 | 4,115 | 2,351 |
Net loss from continuing operations | |||||||||||
- | - | - | - | - | - | -32,260 | -25,986 | -27,971 | - | - | - |
Loss from discontinued operations | |||||||||||
- | - | - | - | - | - | -369 | -452 | -519 | - | - | - |
Net loss on disposal of assets | |||||||||||
- | - | - | - | - | - | -111 | - | - | - | - | - |
Net loss from discontinued operations | |||||||||||
- | - | - | - | - | - | -480 | -452 | -519 | - | - | - |
Net loss | |||||||||||
-7,247 | -7,260 | - | -9,663 | -921 | -1,206 | -32,741 | -26,439 | -28,491 | -21,328 | -25,243 | -27,026 |
Basic and diluted net loss per share from continuing operations | |||||||||||
- | - | - | - | - | - | -0.52 | -0.60 | -0.97 | - | - | - |
Basic and diluted net loss per share from discontinued operations | |||||||||||
- | - | - | - | - | - | -0.01 | -0.01 | -0.02 | - | - | - |
Basic and diluted net loss per share | |||||||||||
-1.70 | -2.41 | -2.76 | -5.94 | 0.04 | -0.16 | -0.53 | -0.61 | -0.99 | -1.50 | -2.05 | -2.55 |
Basic and diluted weighted average common shares outstanding | |||||||||||
4,267 | 2,904 | 2,178 | 963 | - | 47,541 | 61,612 | 43,422 | 28,824 | 14,187 | 12,330 | 10,604 |